ATE86869T1 - Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose. - Google Patents

Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.

Info

Publication number
ATE86869T1
ATE86869T1 AT89850317T AT89850317T ATE86869T1 AT E86869 T1 ATE86869 T1 AT E86869T1 AT 89850317 T AT89850317 T AT 89850317T AT 89850317 T AT89850317 T AT 89850317T AT E86869 T1 ATE86869 T1 AT E86869T1
Authority
AT
Austria
Prior art keywords
treatment
pharmaceutical preparations
interferon gamma
vascular stenosis
interferon
Prior art date
Application number
AT89850317T
Other languages
English (en)
Inventor
Goeran Hansson
Jan Holm
Lena Jonasson
Original Assignee
Goeran Hansson
Jan Holm
Lena Jonasson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goeran Hansson, Jan Holm, Lena Jonasson filed Critical Goeran Hansson
Application granted granted Critical
Publication of ATE86869T1 publication Critical patent/ATE86869T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT89850317T 1988-09-30 1989-09-27 Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose. ATE86869T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
EP89850317A EP0367735B1 (de) 1988-09-30 1989-09-27 Verwendung von Interferon-gamma in pharmazeutischen Zubereitungen zur Behandlung von Gefässstenose

Publications (1)

Publication Number Publication Date
ATE86869T1 true ATE86869T1 (de) 1993-04-15

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89850317T ATE86869T1 (de) 1988-09-30 1989-09-27 Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.

Country Status (18)

Country Link
US (1) US5208019A (de)
EP (1) EP0367735B1 (de)
JP (1) JP2895896B2 (de)
KR (1) KR0137017B1 (de)
AT (1) ATE86869T1 (de)
AU (1) AU623181B2 (de)
CA (1) CA1338722C (de)
DD (1) DD288094A5 (de)
DE (1) DE68905438T2 (de)
DK (1) DK174523B1 (de)
HU (1) HU206988B (de)
IE (1) IE63874B1 (de)
IL (1) IL91796A (de)
NZ (1) NZ230816A (de)
PH (1) PH26293A (de)
PT (1) PT91863B (de)
SE (1) SE462364B (de)
WO (1) WO1990003189A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
CN1119830A (zh) * 1993-01-07 1996-04-03 托马斯·杰弗逊大学 反义抑制C-myc以调节平滑肌细胞的增殖
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
EP0710116B1 (de) * 1993-05-13 2008-09-03 Poniard Pharmaceuticals, Inc. Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
EP0797998A4 (de) * 1995-11-17 2003-01-15 Toray Industries Schutz für endothelzellen
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
NZ506854A (en) 1998-04-02 2003-07-25 Genentech Inc Treatment of cardiac hypertrophy
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2002089828A2 (en) * 2001-05-04 2002-11-14 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU558002B2 (en) * 1981-07-14 1987-01-15 Scotia Holdings Plc Enhancement of 1 series pg production using retinol or carotenoids and linolenic acid
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
JPH04500966A (ja) 1992-02-20
PT91863B (pt) 1995-05-31
DE68905438T2 (de) 1993-09-30
JP2895896B2 (ja) 1999-05-24
IE893123L (en) 1990-03-30
DK56291D0 (da) 1991-03-27
WO1990003189A1 (en) 1990-04-05
DK56291A (da) 1991-05-24
DE68905438D1 (de) 1993-04-22
PT91863A (pt) 1990-03-30
AU4305189A (en) 1990-04-18
KR900701308A (ko) 1990-12-01
DD288094A5 (de) 1991-03-21
HU895542D0 (en) 1991-10-28
PH26293A (en) 1992-04-10
KR0137017B1 (ko) 1998-04-25
AU623181B2 (en) 1992-05-07
DK174523B1 (da) 2003-05-12
US5208019A (en) 1993-05-04
SE462364B (sv) 1990-06-18
HUT57063A (en) 1991-11-28
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
SE8803472D0 (sv) 1988-09-30
EP0367735A1 (de) 1990-05-09
IE63874B1 (en) 1995-06-14
NZ230816A (en) 1997-06-24
CA1338722C (en) 1996-11-19
HU206988B (en) 1993-03-01
EP0367735B1 (de) 1993-03-17

Similar Documents

Publication Publication Date Title
ATE86869T1 (de) Verwendung von interferon-gamma in pharmazeutischen zubereitungen zur behandlung von gefaessstenose.
DK0725648T3 (da) Leverspecifikke farmaceutiske aktivstoffer
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
ATE114113T1 (de) Verwendung von droloxifen bei der behandlung von knochenerkrankungen.
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
EP0376251A3 (en) An anticoagulant substance obtained from urine
DK399288A (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
DE59609099D1 (de) Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate
BR9007115A (pt) Novo trombolitico
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
DE69334087D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
ATE476182T1 (de) Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs
ATE89288T1 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti- cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
DE59407576D1 (de) Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
ATE82685T1 (de) Verwendung von ifn-gamma enthaltenden arzneimitteln zur vorbeugung und behandlung von durch primaere immundefekte verursachte krankheiten.
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
IT9041714A0 (it) Linfa del libro dell'abete rosso (abies picea) per la cura di malattie neoplastiche e da virus in genere
DK0495721T3 (da) Anvendelsen af et polypeptid med en humant-interleukin-2-aktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af pneumothorax
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
JO1708B1 (en) The use of trinitrobenzene or cochineal acid in the treatment of cancer or genital diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time